Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Aug 17, 2026
Reporting period
Not applicable
Filed with the SEC
Aug 19, 2026
CFOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001709954-26-000012
Filed / recorded
Aug 19, 2026, 10:35 PM UTC
Added to OQRO
Oct 7, 2026, 6:56 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
MapLight Therapeutics, Inc.
Issuer CIK
1770069
Ticker
MPLT
Reporting person
Jonathan Gillis
Relationship
Officer
Officer title
CAO and Interim CFO
Security
Voting Common Stock
Table
Non-derivative (Table I)
Transaction date
Aug 17, 2026
Transaction code
A
Shares / units
6,020
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
150,260
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on July 1, 2027, and 1/16th of the RSUs shall vest on each subsequent October 1, January 1, April 1 and July 1 thereafter, subject to the Reporting Person's continued service through each vesting date.
Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.